A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Kissei-Originated Fibroid Drug Approved in Europe
Kissei Pharmaceutical said on June 17 that linzagolix, an oral GnRH receptor antagonist originated by the company, is now approved in Europe for the treatment of uterine fibroids. The drug has been christened Yselty. The European Commission granted the approval…
To read the full story
Related Article
- Linzagolix Gets Label Expansion into Endometriosis in Europe: Kissei
December 24, 2024
- Kissei’s Fibroid Drug Linzagolix Hits German Market
September 18, 2024
- Kissei Won’t Change 2025 Targets Despite Linzagolix Setback, Decide US Plan by March
December 20, 2022
- Swiss Licensee ObsEva Withdraws NDA for Kissei’s Linzagolix in US
August 23, 2022
- Kissei’s Global Plan for Fibroid Med Hits Snag as ObsEva Seeks Restructuring
July 28, 2022
- EU Panel Confirms Nod for Kissei-Originated Fibroid Drug
April 26, 2022
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
BUSINESS
- Daiichi Sankyo Sets Up Advanced Drug-Discovery Lab in San Diego
January 22, 2025
- Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market
January 22, 2025
- DyDo’s 1st Drug Firdapse for LEMS Hits Japan Market
January 22, 2025
- ITP Drug Tavalisse Approved in South Korea: Kissei
January 22, 2025
- Kobayashi Pharma to Revamp Management under New President
January 22, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…